-
Company Insights
Innovation and Patenting activity of Fujifilm Holdings Corp Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Fujifilm Holdings Corp Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Sector Analysis
NewCell and Gene Therapies in Ophthalmology – Disease Overview, Treatment Options and Future Market Assessment
Cell and Gene Therapies in Ophthalmology Market Report Overview The Cell and Gene Therapies (CGT) in ophthalmology market was $46 million in 2023. The market will experience moderate growth during the forecast period with gene therapies targeting Leber congenital amaurosis (LCA) and retinitis likely to be the primary drivers of the CGT market in the ophthalmology space. The CGT in ophthalmology market research report will aid clients in gaining insight into the competitive landscape of leading CGT agents in ophthalmology...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – CYP-001 in Graft Versus Host Disease (GVHD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CYP-001 in Graft Versus Host Disease (GVHD) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CYP-001 in Graft Versus Host Disease (GVHD) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – T-817MA in Alzheimer’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - T-817MA in Alzheimer's Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. T-817MA in Alzheimer's Disease Drug Details: T-817MA is under development for the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Gemcitabine Hydrochloride in Bile Duct Cancer (Cholangiocarcinoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Gemcitabine Hydrochloride in Bile Duct Cancer (Cholangiocarcinoma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Gemcitabine Hydrochloride in Bile Duct Cancer (Cholangiocarcinoma) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Elinzanetant in Vasomotor Symptoms of Menopause (Hot Flashes)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Elinzanetant in Vasomotor Symptoms of Menopause (Hot Flashes) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Elinzanetant in Vasomotor Symptoms of Menopause (Hot Flashes)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Gemcitabine Hydrochloride in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Gemcitabine Hydrochloride in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Gemcitabine Hydrochloride in Non-Small Cell Lung Cancer Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Gemcitabine Hydrochloride in Transitional Cell Cancer (Urothelial Cell Cancer)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Gemcitabine Hydrochloride in Transitional Cell Cancer (Urothelial Cell Cancer) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Gemcitabine Hydrochloride in Transitional Cell Cancer...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Gemcitabine Hydrochloride in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Gemcitabine Hydrochloride in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Gemcitabine Hydrochloride in Solid Tumor Drug Details: Gemcitabine hydrochloride (FF-10832)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – S-65487 in Non-Hodgkin Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - S-65487 in Non-Hodgkin Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. S-65487 in Non-Hodgkin Lymphoma Drug Details: S-65487 is under development for...